Results 101 to 110 of about 14,369,746 (295)

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults

Neuropsychiatric Disease and Treatment, 2013
James Ermer,1 Mary B Haffey,1,† Cynthia Richards,1 Kenneth Lasseter,2 Ben Adeyi,1 Mary Corcoran,1 Beverly Stanton,1 Patrick Martin1 1Shire Development LLC, Wayne, PA, 2Clinical Pharmacology of Miami, Inc., Miami, FL, USA†This author
Ermer J, Haffey MB, Richards C, Lasseter K, Adeyi B, Corcoran M, Stanton B, Martin P   +7 more
doaj  

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Subjective responses predict d-amphetamine choice in healthy volunteers. [PDF]

Pharmacol Biochem Behav, 2021
Murray CH, Li J, Weafer J, de Wit H.
europepmc   +1 more source

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source

Amphetamine-Induced Displacement of [¹¹C]FLB 457 Binding Potential.

, 2016
The bar graph shows [11C]FLB 457 BPND under baseline (white bars) and post-amphetamine (black bars) conditions in n = 31 healthy subjects. Amphetamine led to a significant decrease in five of the eight cortical regions of interest (* denotes p 9–11].
Maureen A. May (2847386), Kelli Fasenmyer (2847377), Divya Tumuluru (2847383), Rajesh Narendran (304516), Michael L. Himes (2847380), W. Gordon Frankle (331205), Vishwajit L. Nimgaonkar (28735), Kodavali V. Chowdari (260174)   +7 more
core   +1 more source

Brain reward function in young people with cannabis use disorder: A functional magnetic resonance imaging study

Addiction, EarlyView.
Abstract Background and Aims Cannabis use disorder (CUD) affects ~50 million people globally. Neuroscientific theories suggest that a blunted neural response to non‐drug rewards is a hallmark of substance use disorders; however, this remains untested in CUD. The current study tested whether brain reward system responses to the anticipation and feedback
Martine Skumlien, Lisa‐Marie Greenwood, Arush Honnedevasthana Arun, Isabella Goodwin, Anastasia Paloubis, Tribikram Thapa Rana, Marianna Quinones Valera, Eugene McTavish, Gabrielle Abbott, Suraya Dunsford, Antonio Verdejo‐Garcia, Jessica Ramamurthy, Mark M. Schira, Nadia Solowij, Chao Suo, Valentina Lorenzetti   +15 more
wiley   +1 more source

d-Amphetamine Transdermal System in Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Secondary Endpoint Results and Post Hoc Effect Size Analyses from a Pivotal Trial. [PDF]

J Child Adolesc Psychopharmacol, 2023
Cutler AJ, Suzuki K, Starling B, Balakrishnan K, Komaroff M, Meeves S, Castelli M, Childress A.   +7 more
europepmc   +1 more source

Prescribed alternative stimulants among people who use unregulated stimulants: Examining the association between maximum dose reached and medication discontinuation in the first 3 years of implementation in British Columbia, Canada

Addiction, EarlyView.
Abstract Background and aims In 2020, British Columbia (BC), Canada, introduced ‘Prescribed Alternatives’ (PA) as an approach to offering regulated substances to people accessing the unregulated supply. This study aimed to estimate and compare prescribing characteristics of dextroamphetamine and methylphenidate stimulant PAs in BC, to estimate ...
Bin Zhao, Kevin Hu, Roshni Desai, Shania Au, Kali‐olt Sedgemore, Vitor Tardelli, Addie Carter, Paxton Bach, Christian Schutz, Amanda Slaunwhite, Alexis Crabtree, Heather Palis   +11 more
wiley   +1 more source

Amphetamine increases vascular permeability by modulating endothelial actin cytoskeleton and NO synthase via PAR-1 and VEGF-R

Scientific Reports
Abuse of amphetamine-type stimulants is linked to cardiovascular adverse effects like arrhythmias, accelerated atherosclerosis, acute coronary syndromes and sudden cardiac death.
Julia Böttner, Tina Fischer-Schaepmann, Sarah Werner, Sarah Knauth, Heinz-Georg Jahnke, Holger Thiele, Petra Büttner   +6 more
doaj   +1 more source